Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX12 | P18054 | 3/20 | 0.67 |
| ▸ | HTT | P42858 | 2/20 | 0.63 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | POLB | P06746 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.42 |
| ▸ | QPCT | Q16769 | 1/20 | 0.42 |
| ▸ | TLR8 | Q9NR97 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10757398 | 0.87 | HTT (0.70) | ALOX12HTTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL10852491 | 0.87 | HTT (0.70) | ALOX12HTTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL10853481 | 0.82 | SMN1; SMN2 (0.76) | ALOX12HTTSMN1; SMN2GAARAB9A | |
| SCHEMBL10756833 | 0.82 | HTT (0.76) | ALOX12HTTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL2361098 | 0.82 | HTT (0.91) | ALOX12HTTSMN1; SMN2GAAALDH1A1 | |
| Nitric Acid SCHEMBL11097781 | 0.81 | HTT (0.51) | ALOX12HTTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL8590214 | 0.80 | ALOX12 (1.00) | ALOX12HTTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL10602306 | 0.78 | HPGD (0.51) | ALOX12HTTSMN1; SMN2ALDH1A1POLB | |
| SCHEMBL5452460 | 0.78 | SMN1; SMN2 (0.69) | ALOX12HTTSMN1; SMN2GAAALDH1A1 | |
| SCHEMBL28472390 | 0.77 | SMN1; SMN2 (0.56) | ALOX12HTTSMN1; SMN2GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9296697-B2 | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors | ABBOTT LABORATORIES (US) | 2016-03-29 | — | — | US | disclosed |
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2010-07-22 | — | — | US | disclosed |
| EP-0116628-B1 | 1-ACYL-3-PYRIDYLMETHYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | RORER INTERNATIONAL (OVERSEAS) INC. (US) | 1989-01-18 | — | — | EP | disclosed |
| EP-0116628-A4 | 1-ACYL-3-PYRIDYLMETHYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS. | RORER INTERNAT OVERSEAS INC (US) | 1985-02-18 | — | — | EP | disclosed |
| EP-0116628-A4 | 1-ACYL-3-PYRIDYLMETHYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS. | RORER INTERNAT OVERSEAS INC (US) | 1985-02-18 | — | — | EP | disclosed |
| US-4496573-A | 1-Pyridylmethyl-3-acyl guanidines | WILLIAM H. RORER, INC. (US) | 1985-01-29 | — | — | US | disclosed |
| EP-0116628-A1 | 1-ACYL-3-PYRIDYLMETHYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS. | RORER INT OVERSEAS (US) | 1984-08-29 | — | — | EP | disclosed |
| EP-0116628-A1 | 1-ACYL-3-PYRIDYLMETHYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS. | RORER INT OVERSEAS (US) | 1984-08-29 | — | — | EP | disclosed |
| WO-1984000963-A1 | 1-ACYL-3-PYRIDYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | RORER INT OVERSEAS (US) | 1984-03-15 | — | — | WO | disclosed |
| WO-1984000963-A1 | 1-ACYL-3-PYRIDYLGUANIDINES AND THEIR USE AS ANTIHYPERTENSIVE AGENTS | RORER INT OVERSEAS (US) | 1984-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184787-A1 | Heataryl-substituted guanidine compounds and use thereof as binding partners for 5-ht5-receptors | HTR5A, HTR2C, HTR1E | ALOX12 1857/4885HTT 61/4885SMN1; SMN2 1825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.